RxDoctor Payments Data

Kristin Biddell

Family · Mentor, OHNPI 1467762989

Payments from drug & device makers

$1,140in general payments, 2019–2025

Across 65 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$280
  • AbbVie$246
  • AstraZeneca$165
  • Amgen$109
  • Astellas Pharma US Inc$78
  • Lilly USA, LLC$61
  • plus $202 from 6 others

What the payments were for

  • Food & beverage$1,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,140 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$64,150
Medicare patients
209
Services billed
1,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide62$89,188
EliquisApixaban70$79,320
JardianceEmpagliflozin52$59,840
JanuviaSitagliptin Phosphate46$53,265
TrulicityDulaglutide35$51,798
OzempicSemaglutide34$38,476
FarxigaDapagliflozin Propanediol32$27,011
WegovySemaglutide12$23,886
ProliaDenosumab11$18,720
Breo ElliptaFluticasone/Vilanterol28$18,001
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$17,447
Tresiba Flextouch U-200Insulin Degludec16$8,887
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$7,549
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,344
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$61$140,98697 claims
PfizerEliquis$19$79,32070 claims
Novo NordiskOzempic, Wegovy$280$62,36146 claims
GSKBreo Ellipta, Anoro Ellipta, Arnuity Ellipta$43$38,27973 claims
AstraZenecaFarxiga$165$27,01132 claims
AmgenProlia$109$18,72011 claims
AbbVieSynthroid$246$2,76940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Mentor

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →